For all investor queries, please contact info@vasomune.com.
Latest News
Vasomune Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment
First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and
December 17, 2020
No Comments
Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19
TORONTO, Ontario – (Business Wire) – November 12, 2020 – Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration
November 12, 2020
No Comments
Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing
Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats
August 18, 2020
No Comments
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause,
August 18, 2020
No Comments